Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3767045 | 0.89 | MAPK1 (0.41) | MAPK1HSD17B10POLBRAB9AKMT2A | |
| SCHEMBL13058786 | 0.88 | RAB9A (0.40) | MAPK1HSD17B10POLBRAB9AKMT2A | |
| SCHEMBL3775160 | 0.88 | MAPK1 (0.40) | MAPK1HSD17B10POLBRAB9AKMT2A | |
| SCHEMBL13001994 | 0.85 | KMT2A (0.42) | MAPK1HSD17B10POLBRAB9AKMT2A | |
| SCHEMBL13058778 | 0.80 | POLB (0.43) | MAPK1HSD17B10POLBRAB9AKMT2A | |
| SCHEMBL13001978 | 0.80 | MAPK1 (0.50) | MAPK1HSD17B10POLBRAB9AKMT2A | |
| SCHEMBL3773062 | 0.78 | MAPK1 (0.45) | MAPK1HSD17B10POLBRAB9AKMT2A | |
| SCHEMBL3766818 | 0.77 | MAPK1 (0.39) | MAPK1HSD17B10POLBRAB9AKMT2A | |
| SCHEMBL14380467 | 0.77 | KMT2A (0.45) | MAPK1HSD17B10POLBRAB9AKMT2A | |
| SCHEMBL3765346 | 0.77 | KMT2A (0.45) | MAPK1HSD17B10POLBRAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7847108-B2 | such as N-[2-(4-bromophenyl)phenyl]-6-trifluoromethyl-2,3-dihydro-1,4-oxathiine-5-carboxamide, used for controlling unwanted microorganisms, for example, bacteria, fungi, yeasts, algae and slime organisms | BAYER CROPSCIENCE AG (DE) | 2010-12-07 | — | — | US | disclosed |
| US-20070004793-A1 | such as N-[2-(4-bromophenyl)phenyl]-6-trifluoromethyl-2,3-dihydro-1,4-oxathiine-5-carboxamide, used for controlling unwanted microorganisms, for example, bacteria, fungi, yeasts, algae and slime organisms | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004793-A1 | such as N-[2-(4-bromophenyl)phenyl]-6-trifluoromethyl-2,3-dihydro-1,4-oxathiine-5-carboxamide, used for controlling unwanted microorganisms, for example, bacteria, fungi, yeasts, algae and slime organisms | Q6ZSR9, PFAS, NIT2 | MAPK1 3590/4885HSD17B10 3877/4885POLB 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.